Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT)

CUSIP: 45719W205

Q1 2025 13F Holders as of 31 Mar 2025

Holder snapshot 6 signals
Share change
+1,403,448
SEC-reported price per share
$2.19
Indexed holders
47
Value change
+$3,027,389
Number of buys
31
Number of sells
6
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
135,127,605

Security key

45719W205

Report period

Q1 2025

Indexed institutions

47

Top holders

10

Ownership snapshot

Top reported holders of IKT - Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ARMISTICE CAPITAL, LLC
Disclosed value leader
Sands Capital Alternative...
Comparable rows
1/15
Latest evidence
31 Dec 2024
13D/G 13F Lead comparable stake: 5% 14 rows are not safely comparable across share classes. 13D/G row: ARMISTICE CAPITAL, LLC Showing 1-6 of 15 holder rows.

Quick read

ARMISTICE CAPITAL, LLC leads the comparable SEC ownership view at 5%.

1 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ARMISTICE CAPITAL, LLC's linked filing trail.
Comparable ownership Top 1
ARMISTICE CAPITAL, LLC 5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ARMISTICE CAPITAL, LLC
13D/G
5%
Reported 13D/G · 31 Dec 2024
$7,975,554
3,529,006 shares
$0 31 Dec 2024
Sands Capital Alternatives, LLC
13F
Company
13F
—
denominator unverified
$35,587,500
10,950,000 shares
— 31 Dec 2024
Soleus Capital Management, L.P.
13F
Company
13F
—
denominator unverified
$20,556,250
6,325,000 shares
— 31 Dec 2024
Fairmount Funds Management LLC
13F
Company
13F
—
denominator unverified
$19,906,250
6,125,000 shares
— 31 Dec 2024
Commodore Capital LP
13F
Company
13F
—
denominator unverified
$19,256,250
5,925,000 shares
— 31 Dec 2024
PERCEPTIVE ADVISORS LLC
13F
Company
13F
—
denominator unverified
$19,256,250
5,925,000 shares
— 31 Dec 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2025

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
47
Shares
51,462,756
Indexed holders
47
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2025 vs Q4 2024 Across Filers

Q4 2024 indexed holders
31
Q1 2025 indexed holders
47
Indexed holder difference
16
Investor Q4 2024 Shares Q1 2025 Shares Share Diff Share Chg % Q4 2024 value Q1 2025 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .